Stay updated on Pembrolizumab for Desmoplastic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Desmoplastic Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab for Desmoplastic Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe record’s last-submitted and last-posted dates changed to November 10 and November 13, 2026, replacing the October dates.SummaryDifference0.0%

- Check9 days agoChange DetectedThe ClinicalTrials.gov record for the pembrolizumab study in resectable or unresectable desmoplastic melanoma is displayed, with details on the study design, eligibility, outcomes, locations, and publications.SummaryDifference100%

- Check16 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, indicating a site software version update.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide notice announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.” The clinical trial study record remains inaccessible.SummaryDifference1%

- Check30 days agoChange DetectedThe footer's site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer’s revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for Desmoplastic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Desmoplastic Melanoma Clinical Trial page.